Vaccines, Free Full-Text

The ideal vaccine against viral infections should elicit antibody responses that protect against divergent strains. Designing broadly protective vaccines against SARS-CoV-2 and other divergent viruses requires insight into the specific targets of cross-protective antibodies on the viral surface protein(s). However, unlike therapeutic monoclonal antibodies, the B-cell epitopes of vaccine-induced polyclonal antibody responses remain poorly defined. Here we show that, through the combination of neutralizing antibody functional responses with B-cell epitope mapping, it is possible to identify unique antibody targets associated with neutralization breadth. The polyclonal antibody profiles of SARS-CoV-2 index-strain-vaccinated rabbits that demonstrated a low, intermediate, or high neutralization efficiency of different SARS-CoV-2 variants of concern (VOCs) were distinctly different. Animals with an intermediate and high cross-neutralization of VOCs targeted fewer antigenic sites on the spike protein and targeted one particular epitope, subdomain 1 (SD1), situated outside the receptor binding domain (RBD). Our results indicate that a targeted functional antibody response and an additional focus on non-RBD epitopes could be effective for broad protection against different SARS-CoV-2 variants. We anticipate that the approach taken in this study can be applied to other viral vaccines for identifying future epitopes that confer cross-neutralizing antibody responses, and that our findings will inform a rational vaccine design for SARS-CoV-2.

Key steps in vaccine development - ScienceDirect

Vaccines, Free Full-Text

Covid-19 Vaccinations: County and State Tracker - The New York Times

COVID-19 vaccine hesitancy: the five Cs to tackle behavioural and

A Brief History of Vaccination

VFC: Vaccines for Children Program

Three Shots for Fall: What You Need to Know - The New York Times

A survey of COVID-19 vaccine acceptance across 23 countries in

Influenza and COVID-19 Vaccination Coverage Among Health Care

Determinants of COVID-19 vaccine acceptance in the US